Naloxone Benzoylhydrazone
CAS : 119630-94-3
Ref. 3D-UEA63094
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- Benzoic acid, 2-[(5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazide
- Benzoic acid, [(5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazide
- N'-[(5β,6E)-3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5-epoxymorphinan-6-ylidene]benzohydrazide
- Naloxone Benzolyhydrazone K3 Opioid Rece Ptor Ag
- [(5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-yliden]benzoic acid hydrazide
- [(5Α)-4,5-Epoxy-3,14-Dihydroxy-17-(2-Propenyl)Morphinan-6-Ylidene]Hydrazide Benzoic Acid
- Naloxone benzoylhydrazone
Naloxone benzoylhydrazone is a potent opioid antagonist that is used to reverse respiratory depression caused by opioid overdose. It is a benzoylhydrazone derivative of naloxone and has been shown to be highly potent, with an affinity for the kappa-opioid receptor that is 10x greater than its affinity for the mu-opioid receptor. Naloxone benzoylhydrazone also antagonizes δ-opioid receptors and dopamine receptors, which may contribute to its analgesic effects. This drug has been studied in biological studies and has shown efficacy in animal models of chronic pain relief.